Phosphate effects vitamin

FUNCTION Maintains the level of calcium in the blood, acting mainly on bone and kidney. In bone, PTH stimulates osteoclast cells to produce bone breakdown with release of calcium and phosphorus (PTH has a similar effect in this regard as vitamin D, but operates by a different mechanism PTH acts through cyclic AMP). In the kidney, PTH increases calcium reabsorption and phosphate excretion (vitamin D, however, increases absorption of both calcium and phosphorus in the kidney). 

Tribasic calcium phosphate is widely used as a capsule diluent and tablet filler/binder in either direct-compression or wet-granulation processes. The primary bonding mechanism in compaction is plastic deformation. As with dibasic calcium phosphate, a lubricant and a disintegrant should usually be incorporated in capsule or tablet formulations that include tribasic calcium phosphate. In some cases tribasic calcium phosphate has been used as a disintegrant. It is most widely used in vitamin and mineral preparations as a filler and as a binder. It is a source of both calcium and phosphorus, the two main osteogenic minerals for bone health. The bioavailability of the calcium is well known to be improved by the presence of cholecalciferol. Recent research reports that combinations of tribasic calcium phosphate and vitamin D3 are a cost-effective advance in bone fracture prevention. ... 

Procedure. A vitamin B complex tablet Is crushed and placed In a beaker with 20.00 mL of a 50% v/v methanol solution that Is 20 mM In sodium tetraborate and contains 100.0 ppm of o-ethoxybenzamIde. After mixing for 2 min to ensure that the B vitamins are dissolved, a 5.00-mL portion Is passed through a 0.45- xm filter to remove Insoluble binders. An approximately 4-nL sample Is loaded Into a 50- xm Internal diameter capillary column. For CZE the capillary column contains a 20 mM pH 9 sodium tetraborate/sodlum dIhydrogen phosphate buffer. For MEKC the buffer Is also 150 mM In sodium dodecylsulfate. A 40-kV/m electric field Is used to effect both the CZE and MEKC separations. 

Although it is being found that vitamin D metaboUtes play a role ia many different biological functions, metaboHsm primarily occurs to maintain the calcium homeostasis of the body. When calcium semm levels fall below the normal range, 1 a,25-dihydroxy-vitainin is made when calcium levels are at or above this level, 24,25-dihydroxycholecalciferol is made, and 1 a-hydroxylase activity is discontiaued. The calcium homeostasis mechanism iavolves a hypocalcemic stimulus, which iaduces the secretion of parathyroid hormone. This causes phosphate diuresis ia the kidney, which stimulates the 1 a-hydroxylase activity and causes the hydroxylation of 25-hydroxy-vitamin D to 1 a,25-dihydroxycholecalciferol. Parathyroid hormone and 1,25-dihydroxycholecalciferol act at the bone site cooperatively to stimulate calcium mobilization from the bone (see Hormones). Calcium blood levels are also iafluenced by the effects of the metaboUte on intestinal absorption and renal resorption. 

PTH is the most important regulator of bone remodelling and calcium homeostasis. PTH is an 84-amino acid polypeptide and is secreted by the parathyroid glands in response to reductions in blood levels of ionised calcium. The primary physiological effect of PTH is to increase serum calcium. To this aim, PTH acts on the kidney to decrease urine calcium, increase mine phosphate, and increase the conversion of 25-OH-vitamin D to l,25-(OH)2-vitamin D. PTH acts on bone acutely to increase bone resorption and thus release skeletal calcium into the circulation. However, due to the coupling of bone resorption and bone formation, the longer-term effect of increased PTH secretion is to increase both bone resorption and bone formation. 

PTH has a dual effect on bone cells, depending on the temporal mode of administration given intermittently, PTH stimulates osteoblast activity and leads to substantial increases in bone density. In contrast, when given (or secreted) continuously, PTH stimulates osteoclast-mediated bone resorption and suppresses osteoblast activity. Further to its direct effects on bone cells, PTH also enhances renal calcium re-absorption and phosphate clearance, as well as renal synthesis of 1,25-dihydroxy vitamin D. Both PTH and 1,25-dihydroxyvitamin D act synergistically on bone to increase serum calcium levels and are closely involved in the regulation of the calcium/phosphate balance. The anabolic effects of PTH on osteoblasts are probably both direct and indirect via growth factors such as IGF-1 and TGF 3. The multiple signal transduction... 

Decrease blood calcium Increase blood calcium decrease blood phosphate activation of vitamin D 3 "Fight-or-flight" response reinforces effects of the sympathetic nervous system Reabsorption of sodium excretion of potassium... 

The a ns wer is a. (Hardman, pp 1525-1528.) Pa r a thyroid ho r m o ne is synthesized by and released from the parathyroid gland increased synthesis of PTI1 is a response to low serum Ca concentrations. Resorption and mobilization of Ca and phosphate from bone are increased in response to elevated PTI1 concentrations. Replacement of body stores of Ca is enhanced by the capacity of PTH to promote increased absorption of Ca by the small intestine in concert with vitamin D, which is the primary factor that enhances intestinal Ca absorption. Parathyroid hormone also causes an increased renal tubular reabsorption of Ca and excretion of phosphate. As a consequence of these effects, the extracellular Ca concentration becomes elevated. 

Homocystinuria can be treated in some cases by the administration of pyridoxine (vitamin Bs), which is a cofactor for the cystathionine synthase reaction. Some patients respond to the administration of pharmacological doses of pyridoxine (25-100 mg daily) with a reduction of plasma homocysteine and methionine. Pyridoxine responsiveness appears to be hereditary, with sibs tending to show a concordant pattern and a milder clinical syndrome. Pyridoxine sensitivity can be documented by enzyme assay in skin fibroblasts. The precise biochemical mechanism of the pyridoxine effect is not well understood but it may not reflect a mutation resulting in diminished affinity of the enzyme for cofactor, because even high concentrations of pyridoxal phosphate do not restore mutant enzyme activity to a control level. 

Much discussion of vitamin D focuses on bone health, though this is by no means the only focus on vitamin D action. One result of l,25(OH)2D action is the upregulation of the synthesis of a calcium-binding protein whose function is to transport dietary calcium across the intestinal mucosa and into the systemic circulation. Phosphate accompanies the calcium. This has the effect of increasing the fraction of dietary calcium that is actually absorbed and is, therefore, potentially useful for bone formation. In addition, l,25(OH2)D has the effect of mobilizing calcium from bone. Both actions tend to raise the extracellular level of calcium. 

Example number 1. Medium for fermentation. The goal of this experiment was to develop a defined fermention medium that was usable for the manufacture of ImuVert The objectives were to evaluate the effect of replacing citrate with a phosphate buffer, yeast extract with vitamins and minerals, casamino acids with casein peptone and high or low O2 levels on the final yield and composition of ImuVert. 

Figure 1. Half Effect Results for Yield (A) or Vesicle to Ribosome Ratio (B). A is the effect of vitamins and yeast extract. B is the effect of casein peptone and casamino acids. C is the effect of dissolved O2. D is the effect of citrate and phosphate. AB is the interaction of yeast extractAdtamin and mineral with casein peptone/casamino acids. AC is the interaction of yeast extractAdtamins and minerals with dissolved O2. BC is the interaction of casein peptone/casamino acids with dissolved O2. CD is the interaction effect of dissolved 2 with the citrate or phosphate.

Orotic acid in the diet (usually at a concentration of 1 per cent) can induce a deficiency of adenine and pyridine nucleotides in rat liver (but not in mouse or chick liver). The consequence is to inhibit secretion of lipoprotein into the blood, followed by the depression of plasma lipids, then in the accumulation of triglycerides and cholesterol in the liver (fatty liver) [141 — 161], This effect is not prevented by folic acid, vitamin B12, choline, methionine or inositol [141, 144], but can be prevented or rapidly reversed by the addition of a small amount of adenine to the diets [146, 147, 149, 152, 162]. The action of orotic acid can also be inhibited by calcium lactate in combination with lactose [163]. It was originally believed that the adenine deficiency produced by orotic acid was caused by an inhibition of the reaction of PRPP with glutamine in the de novo purine synthesis, since large amounts of PRPP are utilized for the conversion of orotic acid to uridine-5 -phosphate. However, incorporation studies of glycine-1- C in livers of orotic acid-fed rats revealed that the inhibition is caused rather by a depletion of the PRPP available for reaction with glutamine than by an effect on the condensation itself [160]. 

The polypeptide parathormone is released from the parathyroid glands when plasma Ca + level falls. It stimulates osteoclasts to increase bone resorption in the kidneys, it promotes calcium reabsorption, while phosphate excretion is enhanced. As blood phosphate concentration diminishes, the tendency of calcium to precipitate as bone mineral decreases. By stimulating the formation of vit D hormone, parathormone has an indirect effect on the enteral uptake of Ca + and phosphate. In parathormone deficiency, vitamin D can be used as a substitute that unlike parathormone, is effective orally. 

Osteomalacia is the condition in which bone becomes demineralised due to deficiency of vitamin D. In this condition parathyroid hormone (PTH) acts on the bone to maintain serum calcium, resulting in demineralisation. Serum calcium is usually normal or slightly low alkaline phosphatase levels are high, reflecting excessive osteoblast activity, and serum phosphate falls as an effect of PTH on the kidney. The same condition in children results in defects in long bone formation, and is termed rickets. 

With the exception of the possible development of a hypervitaminosis associated with high-dose administration of vitamin D2 or D3, the compounds discussed in this chapter are relatively safe. Allergic reactions to the injection of calcitonin and PTH have occurred and chronic use of some bisphosphonates has been associated with the development of osteomalacia. The principal side effects of intravenous bisphosphonates are mild and include low-grade fever and transient increases in serum creatinine and phosphate levels. Oral bisphosphonates are poorly absorbed and can cause esophageal and gastric ulceration. They should be taken on an empty stomach the individual must remain upright for 30 minutes after ingestion. 

Mecfianism of Action Afat-soluble vitamin that is essential for absorption, utilization of calcium phosphafe, and normal calcification of bone. Therapeutic Effect Stimulates calcium and phosphate absorption from small inf esf ine, promof es secretion of calcium from bone fo blood, promofes renal tubule phosphate resorption, acts on bone cells to stimulate skeletal growth and on parathyroid gland to suppress hormone synthesis and secretion. 

Mechanism of Action An antibiotic that forms complexes with DNA, inhibiting DNA-directed RNA synthesis. May inhibit parathyroid hormone effect on osteoclasts and inhibit bone resorption. TherapeuticEffect Lowers serum calcium and phosphate levels. Blocks hypercalcemic action of vitamin Dand action of parathyroid hormone. Decreases serum calcium. 

---